We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Global Regulator of Gene Transcription Identified as Potential Anticancer Drug Target

By LabMedica International staff writers
Posted on 14 Feb 2016
The enzyme MLL1 (histone-lysine N-methyltransferase 2A) was identified as a potential target for anticancer drugs after researchers found that its inhibition prevented tumor development by shutting down the DNA damage response mechanism and suppressed inflammation by blocking the activity of proliferation-promoting genes.

MLL is a histone methyltransferase deemed a positive global regulator of gene transcription. More...
This protein belongs to the group of histone-modifying enzymes and is involved in the epigenetic maintenance of transcriptional memory. Previous observations linked this transcription-associated methyltransferase and oncoprotein to the DNA damage response (DDR), which led investigators at the University of Pennsylvania (Philadelphia, USA) to examine the role of MLL1 in cancer development and in the appearance of age-related inflammation.

They reported in the February 1, 2016, issue of the journal Genes & Development that MLL1 displayed direct epigenetic control over pro-proliferative cell cycle genes. Inhibition of MLL1 repressed expression of pro-proliferative cell cycle regulators required for DNA replication and DDR activation, thus disabling age-related inflammation expression. However, these effects of MLL1 inhibition on age-related inflammation gene expression did not impair oncogene-induced senescence (OIS) and, abolished the ability of the age-related inflammation to enhance cancer cell proliferation. These results demonstrated that MLL1 inhibition may be a powerful and effective strategy for blocking cancerous growth through the direct epigenetic regulation of proliferation-promoting genes.

"Since tumor-promoting inflammation is one of the hallmarks of cancer, these findings suggest that MLL1 inhibitors may be highly potent anticancer drugs through both direct epigenetic effects on proliferation-promoting genes, as well as through the inhibition of inflammation in the tumor microenvironment," said first author Dr. Brian Capell, a medical fellow in epigenetics and dermatology at the University of Pennsylvania. "In cancer, this could be a potent one-two punch, by blocking both proliferation-promoting genes as well as the cancerous inflammation. One could imagine taking an MLL1 inhibitor as a primary treatment, but also as an adjuvant therapy to tamp down the rampant inflammation caused by drugs like chemotherapies."

Related Links:

University of Pennsylvania



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.